Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33666 | 0.85 | TDP1 (1.00) | TDP1L3MBTL1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL5725578 | 0.85 | TDP1 (0.74) | TDP1L3MBTL1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL1585523 | 0.85 | TDP1 (1.00) | TDP1L3MBTL1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL1806105 | 0.84 | TDP1 (0.72) | TDP1L3MBTL1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL31151600 | 0.84 | TDP1 (0.72) | TDP1L3MBTL1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL1806108 | 0.84 | TDP1 (0.72) | TDP1L3MBTL1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL6655711 | 0.84 | TDP1 (0.72) | TDP1L3MBTL1TSHRSMN1; SMN2HSD17B10 | |
| Potassium Ion SCHEMBL15876228 | 0.84 | TDP1 (0.72) | TDP1L3MBTL1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL329162 | 0.82 | TDP1 (0.70) | TDP1L3MBTL1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL29627171 | 0.82 | TDP1 (0.70) | TDP1L3MBTL1TSHRSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915418-B2 | Intermediates and process for the production of optically active quinolonecarboxylic acid derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-03-29 | — | — | US | claimed |
| US-7915418-B2 | Intermediates and process for the production of optically active quinolonecarboxylic acid derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20060135775-A1 | Intermediates and process for the production of optically active quinolonecarboxylic acid derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1632482-A1 | INTERMEDIATES AND PROCESS FOR THE PRODUCTION OF OPTICALLY ACTIVE QUINOLONECARBOXYLIC ACID DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135775-A1 | Intermediates and process for the production of optically active quinolonecarboxylic acid derivatives | NQO2, COASY, DHPS | TDP1 4021/4885L3MBTL1 4326/4885TSHR 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.